Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94909ArticlesСтатьиResearch ArticleClinical studies of rosuvastatin from the GALAXY project in the context of the new EAS/ESC-2016 recommendations on dyslipidemia Part 1Клинические исследования с розувастатином из проекта GALAXY в контексте новых рекомендаций EAS/ESC-2016 по дислипидемиям Часть 1SusekovA. VСусековАндрей Владимирович

д-р мед. наук, проф., проф. каф. клин. фармакологии и терапии

asus99@mail.ruRussian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian FederationФГБОУ ДПО РМАНПО151220171912VOL 19, NO12 (2017)ТОМ 19, №12 (2017)121928122021Copyright ©; 2017, Consilium MedicumCopyright ©; 2017, ООО "Консилиум Медикум"2017Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/94909

Hypercholesterolemia is the most important risk factor for the development and progression of atherosclerosis in almost all populations, including the Russian Federation. Inhibitors of HMG-CoA reductase (statins) - the most well-known and well-studied class of lipid-lowering drugs with a convincing evidence base for reducing the risk of cardiovascular and total mortality. Rosuvastatin (Crestor®) - statin of the 4th generation, used in daily doses of 5-40 mg, has maximal activity in inhibiting HMG-CoA reductase and, accordingly, lowering the level of low-density lipoprotein cholesterol, has been well studied in the clinical studies program GALAXY in the period 2004-2011 In 2016, the European Society for the Study of Atherosclerosis and the European Society of Cardiology (EAS/ESC) on the diagnosis and treatment of dyslipidemias published a regular recommendation, in which statin therapy in patients with high cardiovascular risk is a priority (evidence of IA). This article discusses the role of classical studies of rosuvastatin from the GALAXY project in the light of the recommendations on dyslipidemia in 2016, as well as the current strategy of treatment with HMG-CoA reductase inhibitors in primary prevention patients with type 2 diabetes mellitus, patients with carotid arteriosclerosis, and platelet stabilization issues are discussed on the background of intensive therapy with statins.

Гиперхолестеринемия является самым важным фактором риска развития и прогрессирования атеросклероза практически во всех популяциях, включая Российскую Федерацию. Ингибиторы ГМГ-КоА-редуктазы (статины) - самый известный и хорошо изученный класс гиполипидемических препаратов с убедительной доказательной базой по снижению риска сердечно-сосудистой и общей смертности. Розувастатин (Крестор®) - статин IV генерации, применяемый в суточных дозах 5-40 мг, обладает максимальной активностью в ингибировании ГМГ-КоА-редуктазы и снижении уровня холестерина липопротеидов низкой плотности, хорошо изучен в программе клинических исследований GALAXY в период 2004-2011 гг. В 2016 г. были опубликованы очередные рекомендации Европейского общества по изучению атеросклероза и Европейского общества кардиологов (EAS/ESC) по диагностике и лечению дислипидемий, в которых терапия статинами у больных высокого сердечно-сосудистого риска является приоритетом (степень доказательности IA). В этой статье обсуждаются роль классических исследований розувастатина из проекта GALAXY в свете рекомендаций по дислипидемиям 2016 г., а также современная стратегия лечения ингибиторами ГМГ-КоА-редуктазы в первичной профилактике больных сахарным диабетом типа 2, пациентов с каротидным атеросклерозом, а также рассматриваются вопросы стабилизации атеросклеротических бляшек на фоне интенсивной терапии статинами.

cholesterolstatinsrosuvastatinatherosclerosisdyslipidemiaefficacyхолестеринстатинырозувастатинатеросклероздислипидемияэффективностьFerence B.A, Ginsberg H.N, Graham I. et al. Low-density lipoprotein cause atherosclerotic cardiovascular disease. 1 Evidence from genetic, epidemiologic and clinical studies. A consensus statement from the EAS Consensus Panel. Eur Heart J 2017; 38: 2459-72.Catapano A, Graham I, de Backer G.D. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipideamias. The Task Force for the management of Dyslipideamias. Eur Heart J 2016. DOI: 10.1093/eurheartj/ehw272Blazing M.A, Giugliano R.P, de Lemos J.A et al. On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J 2016; 182: 89-96. DOI: 10.1016/j.ahj.2016.09.004Sabatine M.S, Giugliano R.P, Keech A.C.et al; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376 (18): 1713-22. DOI: 10.1056/NEJMoa1615664Ridker P.M, Everett B.M, Thuren T. et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017. 377 (12): 1119-31. DOI: 10.1056/NEJMoa1707914Schuster H, Fox J. Investigating cardiovascular risk reduction - the Rosuvastatin GALAXY Programme. Exp Opin Pharmacother 2004; 5: 1187-200.Palmer M.K, Nichols S.J, Lundman P. et al. Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database. Eur J Prev Cardiol 2013; 20 (6): 1080-7. DOI: 10.1177/2047487313489875Karlson B.W, Palmer M.K, Nicholls S.J.et al. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 ACC/AHA guidelines? A VOYAGER meta-analysis. Atherosclerosis 2015; 241 (2): 450-4. DOI: 10.1016/j.atherosclerosis.2015.05.029Karlson B.W, Palmer M.K, Nicholls S.J. et al. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis. Eur J Prev Cardiol 2016; 23 (7): 744-7. DOI: 10.1177/2047487315598710Karlson B.W, Wiklund O, Palmer M.K. et al. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother 2016; 2 (4): 212-7. DOI: 10.1093/ehjcvp/pvw006Jones P.H, Hunninghake D.B, Ferdinand K.C. et al; Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther 2004; 26 (9): 1388-99.Инструкция по медицинскому применению лекарственного препарата Крестор® (таблетки, покрытые оболочкой, 10, 20, 40 мг), с учетом изменений №1-10. Регистрационное удостоверение П N015644/01 от 24.03.2009.Stone N.J, Robinson J, Lichtenstein A.H. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the ACC/AHA Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63 (25 Pt B): 2889-934. DOI: 10.1016/j.jacc.2013.11.002. http://www.cvriskcalculator.comHPS3/TIMI55-REVEAL collaborative Group. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med 2017. DOI: 10.1056/NEJMoa1706444Nordestgaard B.G. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res 2016; 118 (4): 547-63. DOI: 10.1161/CIRCRESAHA.115.306249Schuster H; MERCURY-I Study Group. Effects of switching to rosuvastatin from atorvastatin or other statins on achievement of international low-density lipoprotein cholesterol goals: MERCURY-I Trial. J Am Coll Cardiol 2003 (Suppl): 227A-228A, Abs 1010-149.Stender S, Schuster H, Barter P. et al. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY-I trial. Diabet Obesity Metab 2005; 7 (4): 430-8.Ballantyne C.V, Bertolami M, Garcdia H.R. et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY) II. Am Hear J 2006; 151 (5): 975.e1-9.Stalenhoef A.F , Ballantyne C.V, Sarti C. et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eyr Haer J 2005; 26 (24): 2664-72.Huff M.W, Burnett J.R. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Cur Opin Lipidol 1997; 8 (3): 138-45.Raal F, Pappu A.S, Illingworth D.R. et al. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclereosis 2000; 150 (2): 421-8.Ridker P.M, Danielson E, Fonseca F.A. et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359 (21): 2195-207. DOI: 10.1056/NEJMoa0807646Jellinger P.S, Handelsman Y, Rosenblit P.D. et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocrine Practice 2017; 23 (2): 1-87.Ridker P.M., Lonn E, Paynter N.P. et al. Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses From the Contemporary JUPITER and HOPE-3 Randomized Trials. Circulation 2017; 135 (20): 1979-81. DOI: 10.1161/circulationaha. 117. 028271Ridker P.M, MacFadyen J, Cressman M, Glynn R.J. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 2010; 55 (12): 1266-73. DOI: 10.1016/j.jacc.2010.01.020Aspberg S, MacFadyen J, Glynn R.J.et al. Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial. See comment in PubMed Commons below. JAMA Intern Med 2015; 175 (2): 171-7. DOI: 10.1001/jamainternmed.2014.6388Ridker P.M, Pradhan A, MacFadyen J.G.et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380 (9841): 565-71. DOI: 10.1016/S0140-6736(12)61190-8Slejko J.F, Page R.L 2nd, Sullivan P.W. Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. Curr Med Res Opin 2010; 26 (10): 2485-97. DOI: 10.1185/03007995.2010.516994Ridker P.M, Buring J.E, Rifai N, Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score. JAMA 2007; 297: 611-9. www.reynoldsriskscore.orgМуромцева Г.А., Концевая А.В., Константинов В.В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и проф. 2014; 13 (6): 4-11. http://dx.doi.org/10.15829/1728-8800-2014-6-4-11Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой, А.Ю.Майорова. 8-й вып. Сахарный диабет. 2017; 20 (1S): 1-112ю. DOI.10.14341/DM2017S8Betteridge D.J, Gibson J.M, Sager P.T. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (<70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Am J Cardiol 2007; 100 (8): 1245-8.Durington P.N, Tuomiehto J, Hamann A. et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabet Res Clin Pract 2004; 64 (2): 137-51.Crouse J.R 3rd, Raichlen J.S, Riley W.A et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297 (12): 1344-53.Brown G, Albers J.J., Fisher L.D. et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98.Blankenhorn D.H, Azen S.P, Dramsch D.M et al. Coronary Angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993; 119 (10); 969-76.Smilde T.J, van Wissen S, Wollersheim H. et al. Effect of aggressive versus conventional lipid-lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blind trial. Lancet 2001; 357 (9256): 574-81.Pitt B, Waters D, Brown W.V et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus evascularization Treatment Investigators. N Engl J Med 1999; 341 (2): 70-6.Nissen S.E, Tuzcu E.M, Schoenhagen P. et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291 (9): 1071-80.Nissen S, Nicholls S.J, Sipahi I et al. Effect of very high-intensity stain therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 2006; on-line, March 13.Nicholls S.J, Borgman M, Nissen S.E. et al. Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus Atorvastati N). Curr Med Res Opin 2011; 27 (6): 1119-29. DOI: 10.1185/03007995.2011.570746Noyes A.M, Thompson P D. A systematic review of the time course of atherosclerosis plaque regression. Atherosclerosis 2014; 234 (1): 75-84. DOI: 10.1016/j.atherosclerosis.2014.02.007Kataoka Y, Hammadah M, Duggal B. et al. Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. Atherosclerosis 2015; 242 (2): 490-5. DOI: 10.1016/j.atherosclerosis.2015.08.005